G2 Capital Management LLC OH Buys New Position in Johnson & Johnson (NYSE:JNJ)

G2 Capital Management LLC OH purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, Holdings Channel.com reports. The fund purchased 2,570 shares of the company’s stock, valued at approximately $403,000.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Cornerstone Wealth Group LLC grew its stake in shares of Johnson & Johnson by 1.3% in the 4th quarter. Cornerstone Wealth Group LLC now owns 32,291 shares of the company’s stock worth $5,061,000 after purchasing an additional 405 shares during the last quarter. Cassia Capital Partners LLC boosted its holdings in Johnson & Johnson by 2.4% during the fourth quarter. Cassia Capital Partners LLC now owns 4,031 shares of the company’s stock worth $632,000 after buying an additional 94 shares in the last quarter. Braun Bostich & Associates Inc. grew its position in Johnson & Johnson by 327.1% in the fourth quarter. Braun Bostich & Associates Inc. now owns 6,347 shares of the company’s stock worth $995,000 after buying an additional 4,861 shares during the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 20.7% in the fourth quarter. Perigon Wealth Management LLC now owns 117,149 shares of the company’s stock valued at $18,362,000 after buying an additional 20,065 shares in the last quarter. Finally, Mosaic Family Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 2.2% during the 4th quarter. Mosaic Family Wealth Partners LLC now owns 9,973 shares of the company’s stock valued at $1,563,000 after acquiring an additional 218 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Morgan Stanley cut their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Bank of America cut their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, Raymond James lifted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $176.36.

Johnson & Johnson Stock Up 0.2 %

JNJ opened at $144.77 on Thursday. The company has a market capitalization of $348.86 billion, a PE ratio of 10.48, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a fifty-two week low of $143.39 and a fifty-two week high of $175.97. The business has a 50-day moving average of $156.54 and a 200-day moving average of $155.74.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.68 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a $1.24 dividend. The ex-dividend date is Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.